Press Releases

Date Title and Summary Additional Formats
Toggle Summary After Much Anticipation, Cellectar Biosciences Initiates NCI-Supported Phase II Trial of CLR 131 in Multiple Myeloma and Other Blood Cancers
MADISON, Wis., March 30, 2017 (GLOBE NEWSWIRE) -- Madison, Wis. Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused clinical stage biotechnology company, today announces the initiation of a Phase II clinical study of its lead phospholipid drug conjugate (PDC) CLR 131 in patients with
View HTML
Toggle Summary Cellectar Announces Expansion of Relapsed/Refractory Multiple Myeloma Cohort in Phase 2 Trial of CLR 131
Multiple myeloma cohort exceeded pre-specified criteria for clinically meaningful benefit
View HTML
Toggle Summary Cellectar Announces Initiation of Phase II Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma
  Cellectar Expects Results from this 36-Patient, Multi-Center Imaging Trial by Year-End 2014 MADISON, Wis., March 04, 2014, – Cellectar Biosciences, Inc. (OTCQX: CLRB) a biopharmaceutical company developing innovative agents for the detection and treatment of cancer, announced enrollment of the
View HTML
Toggle Summary Cellectar Announces Issuance of U.S. Patent Covering CLR 131 Use in Multiple Myeloma
MADISON, Wis. , April 03, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, announces that the United States Patent and Trademark Office
View HTML
Toggle Summary Cellectar Announces Late-Breaking Poster Presentations at AACR 2018 Featuring PDCs and CLR 131
MADISON, Wis. , March 15, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, announces that results from two preclinical studies highlighting the
View HTML
Toggle Summary Cellectar Announces Updated Median Overall Survival of 26.2 Months from Cohort 1 of CLR 131 Phase 1 Trial in Advanced Multiple Myeloma
MADISON, Wis., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused, clinical stage biotechnology company (the "company"), today announces that the ongoing median overall survival (mOS) from Cohort 1 of the Phase 1 study of its lead PDC™ compound, CLR 131
View HTML
Toggle Summary Cellectar Appoints Industry Veteran Jim Caruso President and Chief Executive Officer
Dr. Simon Pedder to Retire
View HTML
Toggle Summary Cellectar Biosciences Adds Industry Veterans Douglas Swirsky and Frederick Driscoll to Its Board of Directors
MADISON, Wis., April 10, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused clinical stage biotechnology company, today announces it has appointed Douglas J. Swirsky and Frederick W. Driscoll to its board of directors.
View HTML
Toggle Summary Cellectar Biosciences and Pierre Fabre Extend Collaboration for Development of New Phospholipid Drug Conjugates
MADISON, Wis. and CASTRES, France, Oct. 10, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused, clinical stage biotechnology company (the "company"), together with leading French pharmaceutical company Pierre Fabre, today announce the extension of their ongoing
View HTML
Toggle Summary Cellectar Biosciences and Pierre Fabre Laboratories Announce Oncology Research Collaboration
Collaboration to Advance Use of Phospholipid Drug Conjugate (PDC) Platform for Targeted Delivery of a Selection of Pierre Fabre Cytotoxics
View HTML